STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] Roivant Sciences Ltd. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Roivant Sciences Form 144 filing reveals significant insider stock sales by Vivek Ramaswamy, indicating planned disposal of 577,007 shares with an aggregate market value of $6,611,850. The sale is scheduled for June 20, 2025, through Rockefeller Financial LLC on NASDAQ.

Key transaction details:

  • Securities originated as Founder Shares acquired on May 7, 2014
  • Total outstanding shares: 679,806,070
  • Recent trading activity shows substantial sales in past 3 months totaling 2,212,455 shares for approximately $25 million

Previous sales by Ramaswamy in the last 3 months occurred on multiple dates:

  • June 18: 565,266 shares ($6.47M)
  • June 6: 200,800 shares ($2.25M)
  • June 4: 547,430 shares ($6.21M)
  • May 7: 625,000 shares ($6.99M)
  • May 6: 273,959 shares ($3.14M)

Positive

  • None.

Negative

  • Founder and former CEO Vivek Ramaswamy has sold approximately 2.21 million shares worth over $25M in the past 3 months, indicating significant insider selling pressure
  • The planned sale of an additional 577,007 shares ($6.61M) continues the substantial liquidation pattern
  • Total insider sales represent a material reduction in Ramaswamy's founder holdings, potentially signaling decreased confidence in company prospects

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many ROIV shares is Vivek Ramaswamy selling according to the June 2025 Form 144?

According to the Form 144 filing, Vivek Ramaswamy plans to sell 577,007 shares of ROIV common stock through Rockefeller Financial LLC, with an aggregate market value of $6,611,850.11.

What is the total value of ROIV shares sold by Vivek Ramaswamy in the past 3 months before June 2025?

In the three months prior to the filing, Vivek Ramaswamy sold a total of 2,212,455 shares of ROIV common stock for total gross proceeds of approximately $25,057,989.92 across five separate transactions between May and June 2025.

When did Vivek Ramaswamy originally acquire his ROIV shares being sold?

According to the filing, Vivek Ramaswamy acquired 58,409,211 shares on May 7, 2014, as Founder Shares from Roivant Sciences Ltd.

What percentage of ROIV's outstanding shares is Ramaswamy planning to sell?

The planned sale of 577,007 shares represents approximately 0.085% of ROIV's total outstanding shares, which according to the filing is 679,806,070 shares.

What was the largest single ROIV stock sale by Ramaswamy in the past 3 months?

The largest single sale was 625,000 shares on May 7, 2025, which generated gross proceeds of $6,987,387.60.
Roivant Sciences

NASDAQ:ROIV

ROIV Rankings

ROIV Latest News

ROIV Latest SEC Filings

ROIV Stock Data

14.06B
455.99M
26.13%
76.8%
5.72%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
LONDON